TNF-α Inhibitors and Monoclonal Antibodies mABs (WBH with Dr. Saleeby Ep. 17)

Learn more about Whole Body Health: https://covid19criticalcare.com/courses/whole-body-health-with-dr-saleeby/

In this episode of Whole Body Health, Dr. JP Saleeby discusses TNF-α inhibitors and monoclonal antibodies (mABs) as treatments for autoimmune diseases like Crohn’s disease and Rheumatoid Arthritis. Learn what TNF-α blockers are, their uses, and alternatives available. Dr. Saleeby shares concerns about the newness of some mABs, the lack of extensive safety data, and potential side effects.

We’ll also learn about the risks associated with anti-TNF therapy, including reduced immunity leading to infections such as tuberculosis and histoplasmosis, and the possibility of developing certain cancers and autoimmune conditions. Dr. Saleeby emphasizes the importance of being informed about these treatments, their adverse side effects, and why careful consideration is needed before starting therapy with TNF-α inhibitors and monoclonal antibodies

Dr. JP Saleeby | Carolina Holistic Medicine
https://carolinaholisticmedicine.com/

Dr. JP Saleeby's Substack | Yusuf's Substack
https://jpsaleebymd.substack.com/

The FLCCC Alliance is a healthcare nonprofit on a mission to restore trust, integrity, and the doctor-patient relationship. Get involved by clicking below:

• Donate: https://geni.us/Donate-Today

• Follow: https://geni.us/Follow-FLCCC

• Protocols: https://geni.us/Treatment

• Webinar: https://geni.us/FLCCC-Webinar

• Shop: https://geni.us/Shop-FLCCC

Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only. Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.
CSID: 159a72f971c5ac90

Content Managed by ContentSafe.co